Skip to main content
Caplight Logo









NexaBiome

NexaBiome

Private
GlasgowHealthcare & Life Scienceshttps://nexabiome.com/

Last Round

Grant

Jan 22, 2026

Total Funding Raised

$2M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

NexaBiome is a biotechnology company that develops bacteriophage solutions to combat antimicrobial resistance.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts, Data as a Service

AI Layer

Application

Keywords

phage therapyantimicrobial resistanceAMRbacteriophage technologyphage stabilizationantibiotic alternativesdrug-resistant infectionssuperbug treatmentphage formulationanimal healthhuman healthwound carephage librarybiotechnology licensinglivestock healthaquaculture health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NexaBiome Comparables

Compare NexaBiome with similar companies based on industry and business-model similarity.

NexaBiome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Medea Biopharma
83%
Oxford Silk Phage Technologies
79%
Cytophage Technologies
79%

NexaBiome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 22, 2026
VC RoundJan 2, 2024
Follow-on OfferingDec 14, 2022
VC RoundMar 15, 2021

Key People

Founding team and executive leadership

Jason Clark

Chief Executive Officer, Chief Scientific Officer

Executive Team

NexaBiome Investors

Notable investors and investment history

NexaBiome investors
InvestorRounds
London & Scottish Investment PartnersFollow-on Offering, VC Round
Scottish Investment Bank (Scottish Enterprise)Follow-on Offering, VC Round, Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 22, 2026

    $170K grant received from Scottish Investment Bank.

  • Jan 2, 2024

    Raised $13M in a venture round.

NexaBiome Filings

Explore SEC and related filing metadata, where available.

NexaBiome filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NexaBiome's valuation, stock price, and market status.

Is NexaBiome a public or private company?

NexaBiome is a private company.

What is the current stock price of NexaBiome?

NexaBiome is a private company with no public stock price. No recent secondary market data is available.

How much is NexaBiome worth (valuation)?

Valuation information for NexaBiome is not publicly available.

Can I buy NexaBiome stock?

NexaBiome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NexaBiome's last funding round?

NexaBiome's most recent funding round was Grant on January 22, 2026.

Who are the main investors in NexaBiome?

Key investors in NexaBiome include Scottish Investment Bank (Scottish Enterprise).

Will NexaBiome IPO soon?

No public IPO plans have been announced for NexaBiome.

How can I track NexaBiome secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NexaBiome's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersGlasgow
Employee Range13
Year Founded2010
Last FundingJan 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?